Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat allergies
The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide, for use in preventing and/or treating allergy symptoms in an infant or a young child, by increasing propionate production, in said infant or young children.
1. A method of reducing at least one of a frequency, an occurrence, a severity or a duration of and/or treating allergy symptoms in an infant or a young child in need thereof by increasing colonic propionate production in the infant or young child, the method comprising administering to the infant or young child a nutritional composition comprising at least one fucosylated oligosaccharide comprising 2′-fucosyllactose (2′FL) and at least one N-acetylated oligosaccharide comprising lacto-N-neotetraose (LNnT),
wherein the nutritional composition does not include galacto-oligosaccharides (GOS), a total amount of the at least one fucosylated oligosaccharide and the at least one N-acetylated oligosaccharide is 0.1 wt. % to 10 wt. % of the nutritional composition, a total amount of the at least one fucosylated oligosaccharide is 2-4 g/L of the nutritional composition, and a total amount of the at least one N-acetylated oligosaccharide is 0.1-2 g/L of the nutritional composition,
the nutritional composition is administered to the infant or young child in an amount effective to increase the colonic propionate production in the infant or young child, and
the infant or young child was born by C-section.
2. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide further comprises an additional fucosylated oligosaccharide selected from the group consisting of 3′fucosyllactose, difucosyllactose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-fucohexaose, lacto-N-difucohexaose I, fucosyllacto-N-hexaose, fucosyllacto-N-neohexaose I, fucosyllacto-N-neohexaose II, difucosyllacto-N-hexaose I, difucosyllacto-N-neohexaose I, difucosyllacto-N-neohexaose II, fucosyl-para-Lacto-N-hexaose, and combinations thereof.
3. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide comprises a 2′ fucosyl-epitope.
4. The method according to claim 1 , wherein the 2′FL is the only fucosylated oligosaccharide in the nutritional composition.
5. The method according to claim 1 , wherein the at least one N-acetylated oligosaccharide further comprises lacto-N-tetraose (LNT).
6. The method according to claim 1 , wherein the at least one N-acetylated oligosaccharide further comprises para-lacto-N-neohexaose (para-LNnH).
7. The method according to claim 1 , wherein a weight ratio of the at least one fucosylated oligosaccharide to the at least one N-acetylated oligosaccharide is from 1:10 to 12:1.
8. The method according to claim 1 , wherein the nutritional composition comprises at least another oligosaccharide and/or fiber and/or a precursor of a human milk oligosaccharide selected from the group consisting of fructo-oligosaccharides (FOS), xylooligosaccharides (XOS), inulin, polydextrose, sialylated oligosaccharides, N-acetylated oligosaccharides, sialic acid, fucose and combinations thereof.
9. The method according to claim 1 , wherein the composition does not comprise any sialylated oligosaccharide.
10. The method according to claim 1 , wherein the nutritional composition comprises at least one probiotic in an amount of from 10 3 to 10 12 cfu/g dry weight of the nutritional composition.
11. The method according to claim 1 , wherein the nutritional composition is in a form selected from the group consisting of an infant formula, a starter infant formula, a follow-on or follow-up infant formula, a baby food, an infant cereal composition, a fortifier and a supplement.
12. The method according to claim 1 , wherein the infant or young child is at risk of developing an allergy selected from the group consisting of: allergic sensitization, food allergy, atopic dermatitis and eczema, wheezing, asthma, allergic rhinitis, rhino-conjunctivitis, eosinophilic esophagitis, hypersensitivity, anaphylaxis, urticaria, angioedema food intolerance, and allergy deriving from allergenic proteins in food, pollen, animal dander, house dust mite, or venom.
13. The method according to claim 1 , wherein the 2′FL and the LNnT are the only human milk oligosaccharides in the nutritional composition.